Monopar Therapeutics (NASDAQ:MNPR) Director Christopher Starr Sells 8,400 Shares of Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Christopher Starr sold 8,400 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the completion of the sale, the director owned 5,173 shares of the company’s stock, valued at approximately $406,080.50. This represents a 61.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Price Performance

Shares of MNPR traded up $0.32 during mid-day trading on Monday, reaching $78.29. 128,260 shares of the company’s stock were exchanged, compared to its average volume of 210,743. The business’s fifty day simple moving average is $107.25 and its 200-day simple moving average is $82.88. The stock has a market capitalization of $525.33 million, a PE ratio of -36.08 and a beta of 1.50. Monopar Therapeutics Inc. has a 52-week low of $50.07 and a 52-week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. Equities research analysts predict that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on MNPR shares. Morgan Stanley reissued an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a report on Monday, August 17th. Zacks Research cut Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. UBS Group set a $125.00 target price on Monopar Therapeutics in a report on Thursday, July 23rd. Finally, Barclays restated an “overweight” rating and set a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MNPR. Bank of New York Mellon Corp purchased a new stake in shares of Monopar Therapeutics in the second quarter valued at approximately $7,124,000. Siren L.L.C. lifted its holdings in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after acquiring an additional 57,820 shares during the period. ADAR1 Capital Management LLC boosted its position in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Bank of America Corp DE grew its position in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares during the period. Finally, Walleye Capital LLC acquired a new stake in shares of Monopar Therapeutics in the 1st quarter worth approximately $3,458,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.